Member Info for Monkshood

I thought the results were OK. Very volatile price so far, it went 10% up and is now 3.5% down! it will be interesting to see how it settles after the conference call at 9.00.

Compared to pre covid these new deals add so many more headsets each time. If we are going to see this number with most of the zoos installations then revenues are going to rise very quickly.

DWS only has 28% acceptance amongst shareholders for their takeover (and they constitute 17% of this amount)
As nex's share price increases so does its value to sgc shareholders were they to elect for a takeover by nex, the 'jam today' option for long-term II's in sgc could soon look less tempting than than a 'some further jam tomorrow' option of the nex bid.

I'm still in this, top slice or top up according to the price. Topping up again today....

WH Ireland just put out a detailed broker note on IMMO with a recommended fair value of 10p/share.

You also need to take into account the share dilution, extra debt, driver issues and inflationary headwinds, even so it does seem to be very undervalued at the moment. It can move quite quickly so lets see how it goes after this TU.

I guess the concern is that with around 80% of valuations being from the end of last year how representative of their current values is the quoted nav .

It looks like a significant number of II's either want a higher offer for sgc or may prefer the offer from nex. DWS only has 10% acceptance beyond the 17% it purchased.

Hopefully the cyber breach will not prove to be a major problem.
Also reassuringly within the rns -
'The Group will report its results for the half year to 28 February 2022 on 27 April 2022 and confirms that they are comfortably in line with Company compiled consensus'

This is an old page -
'It is currently expected that the bulk of the new installations (including Mandalay Bay) will occur through Q1 2020. All of these can be fulfilled from current stock.'
And further down.
“We remain confident in our business model, and that we will achieve our breakeven target around the end of Q1 2020'

For those that do not know, the White City Development is primarily based around the old BBC site which was purchased by Imperial College in 2009. There are a large number of new buildings belonging to both the college and other interests. There are various spaces devoted to start-ups and translational research. Imperial have moved their entire Chemistry Research Department to the site (along with some of their Oncology research). Their Chemistry Post Graduates are primarily based at the White City Campus so I don't see finding a supply of suitably skilled staff being a problem.

I agree - what is nice about this is it is not open to some of the competing technologies such as Aptamers.

The will be a large station on at Old Oak Common. I think that it will be the interchange between HS2, Great Western and Crossrail.
Avacta are clearly confident that they have a long future ahead otherwise I doubt that they would be investing resources in moving ......sounds very positive to me.

I visit there sometimes, there is a lot going on with some fantastic resources and companies moving in.

AgentB- Off topic (for Avacta) -the Vatic test is interesting, but even they must have been worried when Omicron was first identified. The changes in S were so great that there was an initial concern by some that it may not enter the cells via ACE but use an alternative route used by a couple of other coronavirus. Possibly something to look forward to in the future!

Mutation rates in these proteins were known from other coronavirus. With a couple of exceptions all other companies have targeted N.
I did actually raise the point about this at a q&a back in 2020 and anyone who has been here since that summer knows I have been pretty consistent about this.
I don't recall many of the names commenting about this being around at that time.

The mutation rates of S vers N and higher N/S ratio was known 18 months ago.
They have spent around 16M on diagnostics over the past two years surely for this amount they could have worked up more than one assay in parallel.
Happy with the progress of the oncology side though.

But why has it taken 2 years for them to do this.

Bloomberg's Pret index now has sales at UK airports, stations and suburban areas back to pre covid levels (based to Jan 2020). In the past this has, in some areas, been higher than the sales that were subsequently seen in Smiths results. Smiths results for airports was closer to that seen for the number of Flights. UK flights are now about 20% below their 2019 levels (compared to a comparable date) and normalising rapidly. TSA data for the US has footfall at 90%+ of that in 2019 Vegas has also been returning to higher level of visitors. Even below these levels the company was showing decent revenue's and profit in the US. Todays good results from Moonpig should be mirrored by returns from Funky Pigeon. Hospitals channels should also have resumed normalised levels of trade.
Things will have dipped a bit after their last update in January but should have bounced back quite strongly since. I think that the outlook in the Interim results at the end of April is going to be very positive.

FinnCap have uprated to 80p but their forward looking comments look positive.
'As SCE demonstrates, its ability to scale volumes during FY2022, we should be able to drop this component of risk as well, which would drive the valuation to 100p/share. We calculate that adding (and filling) capacity to £75m revenue would drive the valuation to 150p/share, with plenty of scope to grow well beyond this level.'